Skip to main
PFE

Pfizer (PFE) Stock Forecast & Price Target

Pfizer (PFE) Analyst Ratings

Based on 13 analyst ratings
Hold
Strong Buy 23%
Buy 8%
Hold 62%
Sell 8%
Strong Sell 0%

Bulls say

Pfizer is a leading pharmaceutical firm that is poised for strong growth thanks to its robust portfolio of key products and a growing presence in emerging markets. The company's recent strong quarterly results and a potential guidance upgrade for 2026 also support positive outlook. While there are some risks, such as potential patent challenges and a slower post-LOE growth profile, the company's overall favorable positioning makes it an attractive investment opportunity for long-term growth.

Bears say

Pfizer is facing major patent expirations for its top-selling drugs over the next few years, which will put significant pressure on its overall sales and profitability. This, combined with increasing competition in the pharmaceutical industry and potential challenges to its patents, creates a high level of uncertainty for the company's future growth prospects. Furthermore, concerns about Pfizer's reputation stemming from controversies around pricing and technology transfer for its COVID-19 vaccine have created additional risks for the company. These factors, along with Pfizer's limited M&A flexibility and behind-the-curve capabilities in manufacturing and market access, contribute to a negative outlook on the stock.

Pfizer (PFE) has been analyzed by 13 analysts, with a consensus rating of Hold. 23% of analysts recommend a Strong Buy, 8% recommend Buy, 62% suggest Holding, 8% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Pfizer and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Pfizer (PFE) Forecast

Analysts have given Pfizer (PFE) a Hold based on their latest research and market trends.

According to 13 analysts, Pfizer (PFE) has a Hold consensus rating as of Jul 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $29.08, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $29.08, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Pfizer (PFE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.